Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Roche has commenced its first Phase 1 clinical trial to examine the safety and tolerability of an investigational drug designed to address the cognitive and behavioral deficits associated with Down syndrome.
Subscribe to our email newsletter
The placebo-controlled study will recruit up to 33 individuals in one or two countries.
Roche Neurosciences Disease Translational Area global head Luca Santarelli said their strategy at Roche neurosciences is to specifically address these serious conditions that have no approved, effective or safe treatment.
"This is why we have a strong commitment to neuro developmental disorders, including genetic disorders like Down syndrome or Fragile X, as well as autism spectrum disorders," Santarelli said.
Roche Neurosciences Disease Translational Area Translational Medicine head Paulo Fontoura said the study will target only adults between 18 and 30 years old, but we believe that an earlier intervention in Down syndrome has the potential for a greater medical impact.
"While we are still at the early stage, we are confident that our drug’s mechanism of action can potentially open the door to further promising investigations in upcoming years," Fontoura said.